Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK021 versus placebo in adults with tenosynovial giant cell tumor
NL-OMON59701Phase 3Active, not recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tenosynovial giant cell tumor (TGCT) comparing ABSK021 with Placebo (2 arms). Primary endpoint: 25-Week Objective Response Rate by RECIST 1.1. Started Nov 2023; status: active, not recruiting.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NL-OMON59701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59701.